Neurology · Alcohol Use DisorderTrial Updatecompetitivemid-term

Eli Lilly's Mazdutide Shows Promise in Alcohol Use Disorder Study

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 12:31:41 PM

Assessment confidence: 88% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Eli Lilly's ongoing trial for mazdutide in alcohol use disorder could significantly enhance its portfolio in addiction therapies, positioning the company favorably in a growing market. The outcome of this study may influence competitive dynamics and market share among existing players in this therapeutic area. Regulatory context from FDA (Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026) supports the near-term read. Assessment grounded in 18 ranked evidence items (18 high-relevance).

Strategic Assessment

Success in this trial could enhance Eli Lilly's portfolio in addiction therapies and open new market opportunities. The strongest clinical anchor is A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (ClinicalTrials.gov), entity match (eli lilly). In Neurology · Alcohol Use Disorder, 1 regulatory and 3 competitive items passed relevance filtering for Eli Lilly.

Competitive Pressure

The most relevant competitive pressure comes from Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments (Humanexa Signals) — sponsor/company relevance (lilly). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This study positions Eli Lilly in the emerging market for treatments targeting alcohol use disorder, potentially impacting competitors in this space.

Regulatory Outlook

Regulatory risk is concentrated around Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026 (FDA). Sponsor/company relevance (Lilly). The trial's results will be critical for future regulatory submissions, impacting the approval process and labeling for mazdutide as a treatment for alcohol use disorder.

Key Risks

Elevated medium regulatory exposure for Eli Lilly could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, mazdutide could capture a share of the emerging market for alcohol use disorder treatments, potentially leading to increased revenue and a stronger competitive position for Eli Lilly.
Upside for Eli Lilly may improve if Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial could enhance Eli Lilly's portfolio in addiction therapies and open new market opportunities.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
Outcome from Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026 would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
ClinicalTrials.govhigh relevance
Entity match (eli lilly)
FDA document
View source
Tirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Study
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Hybrid Type 1 Trial of Parent-Based Intervention Addressing Social Media and Adolescent Alcohol Use
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of Stereotype Threat on Impulsivity and Its Relation to Alcohol Use in African Americans: An fMRI Study
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
The Effect of Moxibustion at the Dazhui Point on Hypothermia and Maternal Comfort During Cesarean Delivery: A Randomized Controlled Trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Eli Lilly
Mazdutide
alcohol use disorder market
competitors in addiction therapies

Commercial impact

medium

If successful, mazdutide could capture a share of the emerging market for alcohol use disorder treatments, potentially leading to increased revenue and a stronger competitive position for Eli Lilly.

Regulatory impact

medium

The trial's results will be critical for future regulatory submissions, impacting the approval process and labeling for mazdutide as a treatment for alcohol use disorder.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.